
Atrys Reports 9.7% Revenue Growth and 18.5% EBITDA Increase in First Nine Months of 2026
Atrys Health, a medical company specialising in oncology, telediagnostics, pathological anatomy and nuclear medicine, has reported continued business growth during the first nine months of 2026. The company recorded revenue of €117.1 million, representing an increase of 9.7% compared with the corresponding period of the previous financial year. Its performance was supported by the continued expansion of strategic healthcare services, particularly Oncology and Nuclear Medicine, alongside growing international operations in markets including Mexico and Portugal. The latest financial results also highlight improvements in profitability, operating cash flow and financial structure as Atrys continues implementing its 2026–2028 Strategic Plan.
For the period ended September 2026, Atrys reported gross profit of €49 million, an increase of 6.5% year on year. EBITDA reached €14.2 million, up 18.5% compared with the same period in 2025. The company’s EBITDA margin also improved to 12.2%, compared with 11.3% a year earlier. These figures indicate that EBITDA increased at a faster rate than revenue during the reporting period, reflecting the company’s focus on improving operational efficiency and strengthening profitability across its healthcare businesses.
The company also reported that organic EBITDA, excluding the accounting effects arising from the capitalisation of research and development expenditure, increased by 40.3%. This performance contributed to stronger cash generation, with operating cash flow reaching €11.3 million, representing a significant increase of 152.6% compared with the previous year. Atrys attributed the improvement to its business performance and greater investment discipline, alongside the efficiency measures introduced under its new organisational model.
Atrys Records Stronger Revenue and EBITDA Performance
Atrys closed the first nine months of 2026 with revenue of €117.1 million, reflecting 9.7% growth compared with the same period of the previous financial year. The company’s results demonstrate continued expansion across its specialised healthcare services, with Oncology and Nuclear Medicine remaining important contributors to overall performance.
Gross profit reached €49 million, increasing by 6.5% year on year. Meanwhile, EBITDA rose to €14.2 million, an improvement of 18.5%. The increase in EBITDA was accompanied by an improvement in the EBITDA margin, which reached 12.2%, compared with 11.3% in the corresponding period a year earlier. The improvement in margin indicates that the company generated a higher proportion of EBITDA relative to its revenue during the reporting period.
Another important element of the results was the growth in organic EBITDA. After excluding the accounting effects associated with capitalising research and development expenditure, organic EBITDA increased by 40.3%. This figure provides an additional view of the company’s operating performance after removing the specified accounting impact.
The company also reported operating cash flow of €11.3 million, up 152.6%. Stronger cash generation is an important part of Atrys’s financial strategy because it supports the company’s ability to manage its operations, investment priorities and financial commitments. The results reflect the company’s efforts to combine business growth with greater attention to operating efficiency and cash generation.
New Organisational Model Supports Operational Efficiency
Atrys said its financial performance also reflects improvements resulting from a new organisational model implemented in 2026. The model was designed to simplify the company’s structure and strengthen management control across its operations. Through the changes, Atrys has focused on improving the way its business is organised while reducing selected corporate and operating expenses.
According to the company, the measures implemented have reduced corporate staff costs by 15.1% and operating expenses by 23.3%. These reductions form part of its wider efforts to improve operational efficiency and support stronger profitability.
Simplifying organisational structures can help businesses improve oversight of operations and manage resources more effectively. For Atrys, the new model is intended to strengthen management control while supporting its activities across different healthcare service areas and international markets. The company has linked these efficiency improvements to its stronger EBITDA performance and increased operating cash flow.
The reported reductions in corporate staff costs and operating expenses also demonstrate the importance Atrys is placing on cost management as it continues to expand. The company is seeking to maintain growth in its strategic healthcare services while improving the efficiency of its operating structure.
Financial Position Strengthened Following ASPY Sale
Atrys ended September 2026 with a stronger financial position following the sale of ASPY, which was completed in January for €145 million. At the end of September, the company’s net financial debt stood at €37.5 million, representing a reduction of 78.1% compared with the end of 2025.
The reduction in net financial debt marks an important development in the company’s financial optimisation efforts. Lower debt can reduce the financial burden associated with borrowing and provide greater flexibility as a company manages its future priorities. In Atrys’s case, the improvement also contributed to lower finance costs during the reporting period.
The company reported savings of €6.3 million in finance costs compared with the same period of the previous year. These savings reflect the financial impact of the changes made to its debt position following the ASPY transaction and other financial optimisation measures.
Atrys is also continuing to make progress in restructuring its debt to align its financial arrangements with the requirements of its 2026–2028 Strategic Plan. The objective is to ensure that its financial structure is consistent with the company’s strategic priorities and future business plans.
The combination of reduced net financial debt, lower finance costs and stronger operating cash flow provides an important part of the financial picture for the first nine months of 2026. The company is continuing to focus on financial discipline while maintaining its activities in specialised healthcare services and international markets.
CEO Highlights Progress in Strategy and Healthcare Capacity
Marian Isach, CEO of Atrys, said the company’s latest results reflect progress in implementing its strategy, particularly its focus on profitability, cash flow generation and strengthening healthcare capacity.
Commenting on the performance, Isach said:
“These results reflect the progress we have made in implementing our strategy and our commitment to improving profitability, generating cash flow and strengthening our healthcare capacity. The growth in our strategic areas and the efficiency improvements we are implementing enable us to approach the final stretch of the financial year with confidence that we will meet our targets, whilst maintaining our focus on providing specialised, high-quality healthcare.”
The CEO’s comments highlight the company’s intention to balance financial performance with the development of its healthcare services. Atrys continues to focus on specialised areas including Oncology, Nuclear Medicine, Diagnostic Imaging, telediagnostics and pathological anatomy.
The company’s expansion in international markets is also an important part of its strategy. Mexico and Portugal have contributed to the performance of its international operations, while its activities in Spain and other Latin American markets have supported growth across its healthcare businesses.
Oncology Remains a Major Growth Driver
Oncology continued to be one of Atrys’s strongest-performing business areas during the first nine months of 2026. Revenue in the segment increased by 22.5%, while EBITDA rose by 17.1% compared with the corresponding period of the previous year.
The growth highlights the importance of oncology services within Atrys’s overall healthcare business. The company specialises in providing healthcare services in this area, and the latest results show that Oncology remains a significant contributor to its expansion.
The performance of the segment was supported by developments across the company’s geographical markets, particularly in Latin America. Mexico was an important contributor, with the consolidation of the medical oncology business supporting substantial increases in both revenue and EBITDA.
Atrys is continuing to develop its oncology activities as part of its wider strategy to strengthen its specialised healthcare capacity. The company’s results indicate that this business area remains an important source of revenue growth during the current financial year.
Nuclear Medicine Delivers Significant EBITDA Growth
Nuclear Medicine was another important contributor to Atrys’s performance. The business area recorded a 10.0% increase in revenue during the first nine months of 2026. More notably, EBITDA increased by 157.4%, with the company attributing the performance mainly to the results of its operations in Portugal.
The improvement in Nuclear Medicine profitability demonstrates the contribution of this business area to Atrys’s overall EBITDA growth. Portugal’s performance was particularly relevant, with the company’s Nuclear Medicine revenue in the country increasing by 11.9%.
The growth in this segment forms part of Atrys’s broader efforts to expand specialised healthcare services across its markets. Alongside Oncology, Nuclear Medicine remains one of the company’s key strategic areas as it continues to develop its international operations.
Diagnostic Imaging Maintains Positive Momentum
Diagnostic Imaging also delivered positive results during the reporting period, with revenue increasing by 7.2%. The segment contributed to the company’s overall revenue growth, supported by particularly strong performance in Spain.
In the Spanish market, Diagnostic Imaging revenue increased by 15.4% during the first nine months of 2026. This growth was accompanied by a 5.9% increase in Oncology revenue and continued positive performance in Nuclear Medicine.
Spain remains an important market for Atrys, and the results show that several of its specialised healthcare activities continued to expand there. Nuclear Medicine revenue in Spain increased by 6.5%, while EBITDA rose by 56.4%.
The performance across Diagnostic Imaging, Oncology and Nuclear Medicine demonstrates the contribution of multiple healthcare service areas to Atrys’s domestic business. Rather than relying on a single segment, the company is reporting growth across several areas of its specialised healthcare portfolio.
Portugal Strengthens Profitability and Nuclear Medicine Performance
Portugal continued its recovery in profitability during the first nine months of 2026. Atrys reported a 5.7% increase in revenue in the country, while EBITDA reached €2.4 million, representing a level 6.8 times higher than in the same period of the previous year.
The company attributed the improvement to management measures implemented in the market and the strong performance of Nuclear Medicine. Revenue from Nuclear Medicine in Portugal increased by 11.9%, supporting the country’s overall business performance.
The significant improvement in EBITDA reflects the contribution of the measures taken to strengthen the business’s profitability. It also demonstrates the importance of Portugal within Atrys’s international operations, particularly in the Nuclear Medicine segment.
The company’s performance in Portugal is consistent with its wider focus on improving operational efficiency while developing its specialised healthcare services. The market has become an important contributor to the company’s financial progress during the reporting period.
Latin America Growth Led by Mexico
Latin America delivered one of the strongest regional performances for Atrys during the first nine months of 2026. Revenue in the region increased by 28.2%, with Mexico serving as a major contributor to the improvement.
In Mexico, revenue increased by 131.9%, while EBITDA rose by 216.5%. Atrys attributed this performance to the consolidation of its medical oncology business in the country. The results demonstrate the growing contribution of Mexico to the company’s international operations.
The company also reported the opening of a new centre in Querétaro in October, adding to its existing centre in Sentura. Atrys expects the additional centre to support further business growth and strengthen its healthcare capacity in Mexico.
The expansion provides another development in the company’s efforts to build its presence in the Mexican healthcare market. The new centre is intended to contribute to the development of its operations and support the company’s broader growth plans in the country.
Colombia and Peru also recorded positive performance during the reporting period. Together, the two markets delivered revenue growth of 25.7%, providing additional support to the overall performance of Atrys’s Latin American operations.
The combined results from Mexico, Colombia and Peru highlight the importance of the region within Atrys’s international strategy. The company continues to develop its specialised healthcare services across these markets, with Mexico showing particularly strong growth during the first nine months of the year.
Atrys Maintains Its Full-Year 2026 Financial Targets
Following its performance during the first nine months of 2026, Atrys has maintained its financial targets for the full year. The company continues to expect revenue of €156.5 million, representing an increase of 11% compared with the previous financial year.
Atrys is also maintaining its target of reported EBITDA of €20.5 million, which would represent growth of 34%. In addition, the company expects operating cash flow to reach €13.5 million, an increase of 125% compared with the previous financial year.
These targets reflect the company’s expectations for the final months of 2026. Its progress during the first nine months, including revenue growth, improved EBITDA, stronger cash generation and reduced financial debt, forms the basis of its continued confidence in meeting the full-year objectives.
Maintaining the targets also indicates that Atrys intends to continue focusing on the strategic healthcare areas that have supported its performance so far. Oncology, Nuclear Medicine and Diagnostic Imaging remain important contributors, while the company is continuing to develop its international operations in Mexico, Portugal, Colombia and Peru.
Stronger Financial Performance Supports Atrys’s Healthcare Expansion
Atrys’s first nine months of 2026 demonstrate progress across several financial and operational areas. Revenue reached €117.1 million, EBITDA increased to €14.2 million and operating cash flow rose to €11.3 million. The company also reduced its net financial debt to €37.5 million following the ASPY sale and reported lower finance costs compared with the previous year.
At the business level, Oncology and Nuclear Medicine continued to contribute to growth, while Diagnostic Imaging delivered positive revenue performance. Portugal strengthened its profitability, and Latin America recorded substantial expansion, particularly in Mexico following the consolidation of the medical oncology business.
The company’s new organisational model has also supported cost reductions and stronger management control. With the opening of a new centre in Querétaro and continued development of its international activities, Atrys is working to strengthen its healthcare capacity while pursuing its financial objectives.
As the company moves toward the end of 2026, it remains focused on achieving its full-year revenue, EBITDA and operating cash flow targets. Its latest results highlight the role of specialised healthcare services, international expansion, operational efficiency and financial discipline in its ongoing growth strategy.
Source link: https://www.atryshealth.com/





